[go: up one dir, main page]

PE20020547A1 - Uso de la tolterodina en tratamientos del asma - Google Patents

Uso de la tolterodina en tratamientos del asma

Info

Publication number
PE20020547A1
PE20020547A1 PE2001001035A PE2001001035A PE20020547A1 PE 20020547 A1 PE20020547 A1 PE 20020547A1 PE 2001001035 A PE2001001035 A PE 2001001035A PE 2001001035 A PE2001001035 A PE 2001001035A PE 20020547 A1 PE20020547 A1 PE 20020547A1
Authority
PE
Peru
Prior art keywords
tolterodine
phenylproyl
asthma treatments
asthma
treatments
Prior art date
Application number
PE2001001035A
Other languages
English (en)
Inventor
Per-Goran Gillberg
Staffan Sundquist
Sue K Cammarata
Original Assignee
Upjohn Co
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co, Pharmacia Ab filed Critical Upjohn Co
Publication of PE20020547A1 publication Critical patent/PE20020547A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN METODO PARA EL TRATAMIENTO DEL ASMA , ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA QUE COMPRENDE INHALAR EN AEROSOL O POLVO UN COMPUESTO SELECCIONADO DE TOLTERODINA (2-[(1R)-3-DIISOPILAMINO)-1-FENILPROIL)-4-METILFENOL); HIDROXITOLTERODINA, 1-FENILCICLOPENTANOCARBOXILICO, 2-DIISOPROPILAMINO)ETILO; UTILIZANDOSE DE 0,05mg A 12mg
PE2001001035A 2000-10-24 2001-10-18 Uso de la tolterodina en tratamientos del asma PE20020547A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24289900P 2000-10-24 2000-10-24
US28312001P 2001-04-11 2001-04-11
US31421801P 2001-08-22 2001-08-22

Publications (1)

Publication Number Publication Date
PE20020547A1 true PE20020547A1 (es) 2002-06-12

Family

ID=27399612

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001035A PE20020547A1 (es) 2000-10-24 2001-10-18 Uso de la tolterodina en tratamientos del asma

Country Status (9)

Country Link
US (1) US6538035B2 (es)
EP (1) EP1330241A2 (es)
JP (1) JP2004513099A (es)
AR (1) AR031032A1 (es)
AU (1) AU2002212962A1 (es)
CA (1) CA2422901A1 (es)
MX (1) MXPA03003592A (es)
PE (1) PE20020547A1 (es)
WO (1) WO2002034245A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
BR0206207A (pt) * 2001-10-26 2003-12-23 Pharmacia & Up John Company Compostos de amÈnio quaternário e seu uso como agentes antimuscarìnicos
JP2005511582A (ja) * 2001-11-05 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 抗ムスカリン・エアゾール
MXPA04008037A (es) * 2002-02-19 2004-11-26 Pharmacia Corp Uso de inhibidores de la ciclooxigenasa y de agentes antimuscarinicos para el tratamiento de la incontinencia.
US7005449B2 (en) 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
EP1622606A1 (en) * 2003-04-15 2006-02-08 Pharmacia & Upjohn Company LLC Quaternary ammonium compounds and their use as antimuscarinic agents
MXPA05011225A (es) * 2003-04-18 2005-12-14 Pharmacia & Upjohn Co Llc Politerapias.
US7629358B2 (en) * 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
ES2268987B1 (es) 2005-08-05 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de 3,3-difenilpropilaminas.
NZ570693A (en) 2006-03-20 2011-02-25 Pfizer Ltd Amine derivatives
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
WO2009034432A2 (en) * 2007-09-14 2009-03-19 Pfizer Limited Novel compounds active as muscarinic receptor antagonists
KR101188333B1 (ko) 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
CN110372571B (zh) 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US6124354A (en) 1996-07-29 2000-09-26 Pharmacia & Upjohn Ab Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재

Also Published As

Publication number Publication date
US20020161054A1 (en) 2002-10-31
JP2004513099A (ja) 2004-04-30
MXPA03003592A (es) 2003-06-19
US6538035B2 (en) 2003-03-25
WO2002034245A2 (en) 2002-05-02
CA2422901A1 (en) 2002-05-02
EP1330241A2 (en) 2003-07-30
AU2002212962A1 (en) 2002-05-06
AR031032A1 (es) 2003-09-03

Similar Documents

Publication Publication Date Title
PE20020547A1 (es) Uso de la tolterodina en tratamientos del asma
ES2235311T8 (es) Formulación de budesónida/formoterol para inhalación que tiene una densidad aparente de vertido de 0,30 a 0,36 g/ml, un proceso para preparar la formulación y el uso de la misma.
ECSP034732A (es) Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias
AR041969A1 (es) Medicamento para el tratamiento de la enfermedad pulmonar obstructiva cronica
AR082825A2 (es) Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios
LTPA2014019I1 (lt) Fenetanolamino dariniai, skirti kvėpavimo ligoms gydyti
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
NO20054839L (no) Formulering for en oppmalt-dose inhalator ved anvendelse av hydro-fluor-alkaner som drivmidler
ES2178943B1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
NO20041277L (no) Farmasoytiske preparater for behandling av astma.
IS7814A (is) Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
WO2001051071A3 (en) Transepithelial delivery of glp-1 derivatives
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
CL2008000762A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la psoriasis, diabetes, artritis reumatoide, entre otras enfermedades ( divisional solicitud 1147-02).
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
ATE484551T1 (de) Oberflächenmodifizierte siliciumdioxid- titandioxid-mischoxide
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
CR9626A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato
AR039633A2 (es) Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.

Legal Events

Date Code Title Description
FC Refusal